Segment and Related Information (Tables)

9 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense

Segment revenue and operating income (loss) were as follows during the periods presented:

	Diagnostics			Other			Total
Three months ended March 31, 2020
Revenues	$	150.5		$	13.5		$	164.0
Depreciation and amortization		16.8			1.1			17.9
Segment operating income (loss)		(93.6	)		(40.1	)		(133.7	)
Three months ended March 31, 2019
Revenues	$	200.5		$	16.1		$	216.6
Depreciation and amortization		17.0			1.3			18.3
Segment operating income (loss)		40.6			(34.7	)		5.9
Nine months ended March 31, 2020
Revenues	$	503.6		$	41.8		$	545.4
Depreciation and amortization		50.5			3.8			54.3
Segment operating income (loss)		(46.2	)		(117.2	)		(163.4	)
Nine months ended March 31, 2019
Revenues	$	592.5		$	43.2		$	635.7
Depreciation and amortization		50.7			3.9			54.6
Segment operating income (loss)		96.6			(83.4	)		13.2

	Three months ended						Nine months ended
	March 31,						March 31,
	2020			2019			2020			2019
Total operating income (loss) for reportable segments	$	(133.7	)	$	5.9		$	(163.4	)	$	13.2
Unallocated amounts:
Interest income		0.8			0.7			2.5			2.3
Interest expense		(2.3	)		(3.2	)		(7.7	)		(8.8	)
Other		4.1			(0.1	)		3.8			1.0
Income (loss) from operations before income taxes		(131.1	)		3.3			(164.8	)		7.7
Income tax provision		(15.9	)		(3.6	)		(20.7	)		(1.0	)
Net income (loss)		(115.2	)		6.9			(144.1	)		8.7
Net loss attributable to non-controlling interest		—			—			—			(0.1	)
Net income (loss) attributable to Myriad Genetics, Inc.    stockholders	$	(115.2	)	$	6.9		$	(144.1	)	$	8.8